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Introduction  
In 2010 the European Society of Cardiology’s Peripartum Cardiomyopathy (PPCM) Working Group 
defined PPCM as “an idiopathic cardiomyopathy presenting with heart failure secondary to left 
ventricular (LV) systolic dysfunction towards the end of pregnancy or in the months following 
delivery, where no other cause of heart failure is found. It is a diagnosis of exclusion”1 (Figure 1). It is 
important to appreciate that not all heart failure during pregnancy is due to PPCM.  Other 
cardiovascular conditions can present during pregnancy; for example, pre-exisiting cardiomyopathies 
or previously undiagnosed congenital or valvular heart disease.   
How common is peripartum cardiomyopathy? 
The incidence of PPCM varies between countries and between races within countries.  In Africa, 
amongst predominantly black populations, the incidence is around 1 in 1000 live births1.  There are a 
few countries where PPCM appears to be much more common.  For example, in Nigeria and Haiti an 
incidence of 1 in 100 and 1 in 300 pregnancies respectively has been reported23.  In the United 
States, the incidence in predominantly white populations is between 1 in 1000 and 1 in 4000, but in 
African-American populations it is between 1 in 1000 and 1 in 2000.  The incidence in Europe and 
Australasia is as yet unstudied.  The incidence does appear to be increasing – possibly due to 
increased awareness and diagnosis4.   
It is striking that PPCM is usually recognised when patients are very sick with severe myocardial 
dysfunction5.  It seems very likely that less severe forms of PPCM go undiagnosed, with symptoms 
being ascribed to the stresses around the arrival of a new child or alternative diagnoses.  To establish 
the true incidence of PPCM, a prospective, multicentre, international initiative monitoring thousands 
of women starting normal pregnancies would be necessary.  This might be achievable if cardiac 
biomarkers are identified as a gateway to further investigation (see later discussion of potential 
biomarkers).   
What causes PPCM? 
A number of potential factors have been associated with the development of PPCM.  Environmental 
factors might be important in some regions.  For example, in Nigeria mothers consume more salt 
around the time of birth.  Viruses, dietary deficiencies and inflammation have been reported to be 
associated with PPCM, but no strong evidence points to a causative role6.   
Risk factors that have been associated with PPCM include increasing age, multiple births, black and 
Asian race7 and hypertension/pre-eclampsia8.  Whether or not pre-eclampsia is a distinct entity or an 
over-lapping condition is the subject of debate.  The most important clinical issue is to identify and 
treat hypertension, heart failure and left ventricular dysfunction if present.   
Two mechanisms have recently been proposed as likely causes of PPCM.  One involves the pituitary 
hormone prolactin and the other placental soluble fms-like tyrosine kinase 1 (soluble-Flt1).   
Elegant animal models have demonstrated that, during pregnancy, excessive oxidative stress can 
lead to prolactin being cleaved by cathepsin D into an abnormal 16kDa form which can damage the 
heart and blood vessels (e.g. through apoptosis of endothelial cells)910.  In murine models, treatment 
with bromocriptine (which suppresses prolactin) reverses experimental PPCM.  The 16kDa prolactin-
mediated damage has been shown to involve micro-RNA 146a.  Levels of this are elevated in patients 
with PPCM, emphasising the relevance of this in humans.  Discovery of the 16kDa prolactin pathway 
has led to bromocriptine being advocated as a treatment for patients with PPCM.  Bromocriptine as 
a therapy will be discussed later in this article.  Micro-RNA 146a might also represent a diagnostic 
biomarker tool and could conceivably also be a therapeutic target.   
Soluble-Flt 1 is secreted by the placenta and acts by inhibiting vascular endothelial growth factor 
(VEGF) signalling leading to endothelial dysfunction and causing angiogenic imbalance.  Soluble-Flt 1 
plasma levels are higher towards the end of pregnancy in patients with PPCM11.  Increased levels of 
soluble-Flt1 are associated with worse clinical outcomes12.  That both 16kDa prolactin and soluble-
Flt1 are elevated in patients at the time when PPCM manifests suggests a role for both these 
pathways in the development of PPCM.  It may also provide a link between pre-eclampsia and 
PPCM.  
A potentially beneficial hormone in PPCM is relaxin-2. Relaxin is produced in the ovaries, breast and 
placenta with receptors in the heart, smooth muscle and connective tissue.  It has a variety of 
haemodynamic effects, including increased cardiac output and decreased systemic vascular 
resistance, as well as anti-inflammatory and anti-fibrotic properties.  Higher levels of relaxin-2 are 
associated with increased rates of myocardial recovery13.  A recent trial of relaxin in acute heart 
failure (not in PPCM) reported no reduction in cardiovascular death or worsening heart failure14. The 
roles of soluble-FLt1, 16kDa prolactin and relaxin-2 are summarised in Figure 2. 
Familial occurrence has been described in PPCM, suggesting a possible role for a genetic pre-
disposition. However, pregnancy may also unmask a previously undiagnosed familial 
cardiomyopathy 15.  PPCM shares similar genetic findings with patients with dilated cardiomyopathy 
of other mechanisms16. A recent study found that 15% of individuals have a pathogenic genetic 
mutation, most commonly truncating variants in the titin (TTN) gene. As this field evolves, we will 
hopefully find out which patients have a primary genetic cardiomyopathy and how many have PPCM 
with a genetic pre-disposition.     
Presentation of PPCM 
PPCM most commonly presents post-partum and most commonly in the week after birth1718.  The 
European Society of Cardiology PPCM Working Group removed the artificial time cut offs that had 
been a feature of previous definitions1.  A sizeable proportion does present pre-partum.     
Symptoms and signs of PPCM 
Distinguishing symptoms of PPCM from those of normal pregnancy is not easy.  Shortness of breath, 
fatigue and ankle oedema are not specific to PPCM.  When a woman reports orthopnoea, 
paroxysmal nocturnal dyspnoea or marked ankle swelling, PPCM should be suspected.  The non-
specific nature of presenting complaints, as well as lack of awareness of the condition, often results 
in delayed diagnosis.  Persistent cough, palpitations or right hypochondrial pain should raise 
suspicion.  Women can present with symptoms of thromboembolic complications of PPCM, for 
example unilateral leg swelling (deep venous thrombosis), stroke or acute limb ischaemia (arterial 
embolisation). Around 6% of patients with PPCM experience thromboembolic complications4.  Signs 
of PPCM can include those normally found in patients with heart failure, but basal crackles are less 
common (as they are in other cohorts of young versus older patients with heart failure19).  
Tachycardia, elevated jugular venous pressure, a third heart sound and displaced apex beat are 
common.    
Investigations 
The diagnostic approach to suspected PPCM is illustrated in Figure 3. When PPCM is suspected, an 
electrocardiogram, natriuretic peptide measurement and echocardiogram should be performed 
urgently.  Cardiological review should follow any abnormal results. A chest x-ray is not diagnostic in 
the assessment of PPCM as heart size cannot be determined accurately. However, a chest x-ray may 
be required to investigate the cause of breathlessness if unclear.  Chest x-ray in pregnancy should be 
considered safe, with a negligible radiation dose.  Differentiating PPCM from other cardiovascular 
and non-cardiovascular causes of symptoms during pregnancy is often challenging.  The major 
differential diagnoses are listed in Table 1. BNP and NT-proBNP are not elevated in normal 
pregnancy so can be useful to diagnose PPCM20.  There is a suggestion that microRNA 146a might 
prove to be a biomarker specific for PPCM, but this is not yet validated sufficiently to be 
recommended in clinical practice10.  The most common finding on an electrocardiogram is a sinus 
tachycardia.  ST segment and T wave changes are also common21.  Echocardiography in PPCM is 
characterised by left (and often right) ventricular dilatation and dysfunction. As left ventricular 
systolic function is normal or even hyperdynamic in pregnancy, any quantitatively- or qualitatively-
reported impairment of left ventricular systolic function should prompt further assessment. 
Secondary mitral regurgitation is common.  Left ventricular thrombus is common.  There are no 
specific features of PPCM on cardiac magnetic resonance imaging, but it can complement the 
information provided by echocardiography (e.g. it is more sensitive for detecting thrombus) and is 
considered to be safe in pregnancy. Gadolinium contrast agent is usually avoided as its safety in 
pregnancy is unknown.  
Delivery of a patient with PPCM 
When PPCM is diagnosed pre-partum, an urgent assessment by a multidisciplinary team involving 
cardiologists, obstetricians, neonatologists and anaesthetists is necessary.  Involvement of cardiac 
surgeons (if it is felt likely that mechanical circulatory support may be required) should also be 
considered.  Timing, mode and location of delivery should be the focus of discussion between the 
clinical team and the patient as early as possible, and should take into account the patient’s wishes. 
Women with PPCM should be delivered in a high-risk obstetric or cardiac unit by a specialist 
multidisciplinary team with expertise in managing pregnancy in women with cardiac disease. There 
should be access to level 3 intensive and neonatal intensive care units.  Clinical status of the mother, 
severity of left ventricular dysfunction, and growth of the foetus are all markers that are used to 
guide when and how a woman with PPCM delivers. Spontaneous vaginal delivery is often possible, 
but Caesarean section is preferred if the mother is critically ill. Steroids should be given before 
delivery for neonatal lung maturity.   
Outcomes of PPCM 
Death 
PPCM had the lowest mortality of all causes of dilated cardiomyopathy in one large series22.  The 
only major study of in-hospital mortality of PPCM reported that 1.3% of women with PPCM died23.  
Studies from different countries report widely varying mortality rates.  The 6-month mortality rate 
was reported to be around 15-30% in most series enrolling in the 1990s or early 2000s243, although 
most of these studies were conducted in Africa or Haiti.  Recent studies have reported markedly 
lower death rates.  The IPAC (Investigation of Pregnancy-Associated Cardiomyopathy) multicentre 
study of 100 patients in the Unites States of America reported a 1-year mortality rate of 4%25.   Low 
mortality rates have been reported in Pakistan (0% at 6 months), Japan (4% at 6 months) and 
Germany (2% at 6 months)262728.  Mortality rates appear to be higher in black compared to white 
populations1, and higher mortality rates are reported from South Africa and Turkey293031.  Although 
late deaths have been reported in the literature, few studies have examined long-term mortality 
rates.   
Myocardial recovery 
The common question that follows a diagnosis of PPCM is: can cardiac function recover?  Certainly, 
PPCM is the sub-type of cardiomyopathy with the greatest rate of myocardial recovery.  Older 
studies, predominantly from Africa, reported that by 6 months around 30% of patients displayed 
evidence of myocardial recovery.  The recent IPAC study reported much greater recovery rates than 
had been previously; 72% had an ejection fraction of greater than 50% and 52% greater than 55% at 
1 year25.     
Can we predict myocardial recovery? 
Those who present with the lowest ejection fraction are the least likely to recover25.  Those with low 
NT-proBNP or troponin levels are more likely to recover32.  There are no accurate predictors of 
whether or not myocardial recovery will occur.  The lack of ability to predict recovery makes clinical 
decision-making difficult as a patient with initially low ejection fraction may recover; therefore the 
use of implanted cardioverter defibrillators, ventricular assist devices or transplantation may have 
been unnecessary if used too early.  
Maternal/ child bonding and psychology 
Being diagnosed with PPCM is traumatic for the mother, father and family.  Every effort should be 
made to allow for the mother and child to be together.  Remote baby monitors can be used.  Formal 
psychological support should be offered to the family. 
Breast-feeding 
The advantages and disadvantages of breast-feeding should be discussed with the mother33.  
Although there are few hard data, angiotensin converting enzyme (ACE) inhibitors, beta-blockers 
and spironolactone are generally considered safe in breastfeeding34. Most guidance does, however, 
recommend avoiding ACE inhibitors in the first few weeks after delivery, particularly in pre-term 
infants due the risk of neonatal hypotension. The amount of beta-blocker and spironolactone 
present in breast milk is negligible. The use of warfarin is also considered safe. If bromocriptine is 
used, breast-feeding is suppressed.  Involving a pharmacist in prescribing is wise.  There have been 
concerns about the impact of breastfeeding on maternal health in women with heart failure 
(especially women who are critically ill), but also the impact of withholding breastfeeding on 
bonding and child health. 
Treatment 
There are as yet no specific treatments for PPCM, but marked progress in understanding 
pathogenetic mechanisms may lead to targeted treatments.  Current pre-delivery, post-delivery and 
long-term management is summarised in Figure 4. 
Pharmacological therapy 
Before delivery 
Before delivery, patients with symptomatic PPCM should receive diuretics. Although patients are 
commonly given advice about fluid and salt restriction, there is a lack of evidence to support this 
recommendation. Diuretics result in improved symptoms and clinical status.  It has been proposed 
that diuretics reduce placental flow, but this is not the experience in clinical practice (in fact 
placental flow is likely to be improved with improved haemodynamic status).  ACE inhibitors and 
angiotensin receptor blockers are not recommended during pregnancy as they are associated with a 
diverse range of congenital abnormalities.  The combination of hydralazine and nitrates is thought to 
be safe.  Beta-blockers can be used with caution if the patient is stable and euvolaemic, although 
foetal growth screening is recommended.  Mineralocorticoid receptor antagonists and ivabradine 
are not recommended during pregnancy due to lack of safety data.   
After delivery 
After delivery, standard pharmacological treatment for heart failure due to left ventricular 
dysfunction should be started.   
Anticoagulation 
Treatment dose anticoagulation should be used if there is left ventricular thrombus or atrial 
fibrillation.  As pregnancy and heart failure are both pro-coagulant conditions, and the frequency of 
thromboembolic events is in the region of 6%, anticoagulation should be considered in all patients 
after diagnosis. Heparin is used to anticoagulate pre-partum and low molecular weight heparin or 
warfarin is used postpartum.  Some countries choose to use prophylactic dose low molecular weight 
heparin only, while others use treatment dose.  There is no consensus as to how long to continue 
anticoagulation after delivery.  Some argue that, as the pro-coagulant effects of pregnancy are low 
after 6 weeks, anticoagulation should be stopped.  Others continue until 6 months or until 
substantial recovery in cardiac function is seen.  Confidence in stopping anticoagulants is increased if 
cardiac function improves.   
Inotropic support 
A very small randomised placebo-controlled trial of levosimendan against placebo did not 
demonstrate benefit35.  The management of acute severe PPCM-related heart failure has recently 
been reviewed by the European Society of Cardiology’s Heart Failure Association’s PPCM Working 
Group.  Recommendations for inotropes are essentially the same as other causes of acute heart 
failure with the exception of a recommendation to avoid catecholamines if possible36 (Figure 5).     
Should bromocriptine be used to treat PPCM? 
As described above, there is good evidence that the abnormal 16kDa prolactin fragment pathway is 
associated with the pathogenesis of PPCM. Given that bromocriptine suppresses the production of 
prolactin, this has been proposed as a treatment (but it means a mother cannot breastfeed).  In 
2010, a randomised trial of bromocriptine therapy was published37.  20 patients were randomised to 
placebo or bromocriptine.  Bromocriptine was associated with greater recovery of left ventricular 
function.  4 of 10 patients died in the placebo arm and 0 of 10 died in the bromocriptine arm.  
Bromocriptine was also associated with greater recovery in left ventricular function in a non-
randomised study of 96 patients in Germany28.  A randomised trial is nearing completion in Germany 
and is eagerly awaited (Clinicaltrials.gov NCT00998556). However, data from the initial randomised 
trial of 20 patients suggested that the growth curves of the children of mothers randomized to 
bromocriptine or standard care were normal compared to World Health Organization standard 
curves37.   Bromocriptine use in the USA is subject to a black box warning due to increased 
thromboembolic risk.  Its use varies due to the lack of strong evidence, with only 1% of the IPAC USA 
cohort receiving the drug compared to 57% in the cohort from Germany25.   
Should medical therapy be withdrawn in patients whose hearts recover after PPCM? 
Women who have echocardiographically-recovered myocardial function after PPCM are usually keen 
to stop their medical therapy.  There are limited data to guide this decision.  One study of 15 
patients found no deterioration in left ventricular function after 2 years off therapy38.  Some patients 
with apparently normal left ventricular function have abnormal contractile reserve on stress 
echocardiography39.  Anecdotally, some women do have deterioration in cardiac function after 
withdrawal of therapy.  Withdrawal decisions should be discussed with the patient and family and 
sequential withdrawal of treatment seems reasonable with monitoring of cardiac function.   
Implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy (CRT) 
It is a concern when patients with PPCM are about to be discharged with on-going (often very 
severe) severe left ventricular dysfunction. In observational cohorts, sudden death is commonly 
reported as the mode of death, with 38% of deaths reported as sudden in one study from the USA40.  
There are few data of the efficacy of ICDs in cohorts with PPCM.  It is tempting to consider 
implanting an ICD.  As with all causes of heart failure, guidelines suggest a period of best medical 
therapy before considering ICD implantation.  Since most patients with PPCM show some recovery 
of left ventricular function, it is wise to wait until at least 6 months after diagnosis.  A similar 
argument can be made for delaying CRT for around 6 months.   
Wearable cardioverter defibrillators 
To “bridge” the gap between severe left ventricular dysfunction and potential myocardial recovery, 
some have advocated wearable cardioverter defibrillators.  In one single-centre observational cohort 
from a tertiary referral centre, 7 patients were provided wearable cardioverter defibrillators and 3 
had appropriate therapies for ventricular dysrhythmias41.  Another retrospective study of 107 
patients reported no shocks in a cohort of 107 patients wearing cardioverter defibrillators42.  A 
multicentre trial would be valuable to establish if these devices are beneficial.    
Mechanical circulatory support and cardiac transplantation 
Around 5% of patients with PPCM receive a left ventricular assist device (LVAD) or undergo cardiac 
transplantation1.  Some have reported that LVADs are associated with recovery of left ventricular 
function in PPCM, although explantation of LVADs is not common.  Care should be taken to ensure 
that these devices are necessary and that the patient would not recover with optimal 
pharmacological therapy alone. Outcomes of patients with PPCM undergoing LVAD implantation do 
appear to be better than general cohorts with dilated cardiomyopathies43.  Cardiac transplantation is 
sometimes necessary in those who struggle despite optimal management.  Outcomes of patients 
with PPCM appear worse than other aetiologies undergoing cardiac transplantation, with higher 
rates of rejection and mortality44.  Some patients do undeniably present in extremis and warrant 
short-term mechanical circulatory support.   
Contraception and further pregnancy 
Patients must be counselled with regard to contraception and the potential risk of future 
pregnancies. This counselling should take place before discharge and, ideally, a contraceptive 
solution be provided. Counselling about future pregnancy risk will need to be reassessed as the 
patient progresses and should involve both a cardiologist with expertise in cardiac obstetrics and an 
obstetrician. 
Contraception 
Progesterone-only coils, implants/injectables or progesterone-only pills are the preferred mode of 
contraception.  Oestrogen-containing combined oral contraceptives are not recommended, both 
because they are pro-thrombotic and because they increase fluid retention, which may exacerbate 
cardiac disease.  Barrier methods are not sufficiently reliable1.  
Future pregnancies 
Historically patients with PPCM were advised not to have further pregnancies.  Women should now 
be offered careful assessment and pre-pregnancy counselling by a combined cardiac obstetric team 
to help them and their partner decide how they wish to proceed in terms of future pregnancy.  If left 
ventricular function has recovered there is a risk of recurrent heart failure of around 25% during a 
subsequent pregnancy45.  The risk of dying is very low if myocardial recovery has occurred.  Not 
surprisingly, if left ventricular function has not recovered, the risk of subsequent pregnancy is higher.  
Mortality seems to be around 16%, with the risk of recurrent heart failure around 50%45.  Future 
pregnancies should be managed by a multidisciplinary cardiac and obstetric team.  Ideally, patients 
should have a period off pharmacological therapy before conception to ensure that left ventricular 
function does not deteriorate.  Stress testing (preferably exercise stress echocardiography) can be 
useful prior to conception to assess myocardial reserve and guide decision-making46. Patients should 
be monitored closely with serial assessments of cardiac function and natriuretic peptides.   
The Heart Failure Society of the European Society of Cardiology’s PPCM Registry 
The sparsity of data regarding PPCM prompted the Heart Failure Society of the European Society of 
Cardiology’s PPCM Registry47.  This aims to collect comprehensive data on baseline characteristics, 
treatment and outcomes in 1000 women with PPCM.  As of January 2017, over 525 patients have 
been entered. Patients who have presented within the last 6 months with PPCM are eligible for 
inclusion (for further details and to join the registry e-mail: eorp@escardio.org). 
The future 
Increased awareness of PPCM is the primary aim of the coming years.  New specific diagnostic 
techniques may emerge from improved understanding of the pathological pathways.  Perhaps 
groups of patients with PPCM have different responsible pathological processes which would 
warrant tailored therapeutic approaches.  Better prognostic scores or tools would allow treatment 
of those who are likely to benefit and avoidance of unnecessary therapies in others.  Early 
recognition and focussed management in combined cardiology and obstetric teams should lead to 
even better outcomes.  
Summary and conclusions 
PPCM is uncommon, but not rare.  The pathogenesis is increasingly understood and involves 
hormonal and vascular processes which damage the cardiovascular system.  These pathways have 
the potential to be used to develop novel diagnostic and therapeutic approaches.  Mortality rates 
are lower than were historically reported and myocardial recovery rates are improving, but there 
remains a need for improved outcomes in this cohort of young patients. Contraceptive advice and 
counselling about the risk of subsequent pregnancies should be offered to all patients.   
 
 
  
Learning objectives 
PPCM should be suspected in women towards the end of pregnancy or in the months following 
delivery if they have symptoms or signs of heart failure.   
Investigations for suspected PPCM should include an electrocardiogram, BNP or NT-proBNP and an 
echocardiogram.     
Most women with PPCM recover to normal cardiac function over 12 months on conventional 
medical therapy for heart failure.  Mortality has fallen to <10% at 1 year.   
Women with PPCM must be advised about contraception to avoid unplanned conception on 
teratogenic drugs for heart failure.   
Women should be counselled with respect to the potential risk of future pregnancies.    
Patients should be managed by a team involving cardiologists, anaesthetists and obstetricians. 
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Figure 1 – European Society of Cardiology PPCM Working Group defintion of PPCM 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peripartum cardiomyopathy is an idiopathic 
cardiomyopathy presenting with heart failure 
secondary to left ventricular (LV) systolic 
dysfunction towards the end of pregnancy or 
in the months following delivery, where no 
other cause of heart failure is found. It is a 
diagnosis of exclusion. The LV may not be 
dilated but the ejection fraction (EF) is nearly 
always reduced below 45%. 
 
Figure 2 – Pregnancy hormones in PPCM 
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Figure 3 – Diagnostic approach to suspected PPCM 
 
 
 
 
 
 
 
 
 
 
 
 
Symptoms suggestive of PPCM 
Non-specific – ankle swelling, shortness of breath 
More specific – orthopnoea, persistent cough, paroxysmal 
nocturnal dyspnoea 
Urgent ECG 
BNP or NT-proBNP 
Urgent echocardiography 
                               Cardiology review 
Any abnormality 
Table 1 – Differential diagnosis of PPCM 
 Distinguishing features 
Cardiovascular conditions 
Pre-existing idiopathic or familial DCM unmasked 
by pregnancy 
 PPCM most commonly presents towards the end of pregnancy or post 
partum whereas DCM usually presents by the 2nd trimester 
  
Pre-existing valvular heart disease unmasked by 
pregnancy 
 PPCM most commonly presents towards the end of pregnancy or post 
partum whereas valvular heart disease usually presents by 2nd 
trimester 
Pre-existing congenital heart disease  PPCM most commonly presents towards the end of pregnancy or post 
partum whereas congenital heart disease usually presents by 2nd 
trimester 
Pre-eclampsia  Pre-eclampsia usually presents during pregnancy and is associated 
with proteinuria and hypertension 
Pregnancy associated myocardial infarction  History and electrocardiogram +/- coronary angiography should 
distinguish  
Pulmonary embolus  History / ECG / CXR 
Non-cardiovascular conditions 
Anaemia  Low haemoglobin 
Depression, lack of fitness  These should be distinguishable following history and examination, 
such as weight gain 
DCM – dilated cardiomyopathy; PPCM – peripartum cardiomyopathy 
  
Figure 4 – PPCM management 
 
Pre-delivery 
- diuretics if symptomatic 
- anticoagulation (heparin) 
- beta-blockers if definitely euvolaemic 
- hydralazine and nitrate (especially if BP 
elevated) 
- monitor with cardiac imaging and 
biomarkers 
- delivery plan (with obstetric team) 
 
Post-delivery 
- conventional medical therapy for heart 
failure 
- low molecular weight heparin or 
warfarin  
- heart failure team follow-up 
- counselling re contraception 
- counselling re subsequent pregnancy 
- consider psychological input 
Long-term 
- On-going counselling re contraception 
and subsequent pregnancy 
- if persisting severe left ventricular 
dysfunction consider ICD 
- if myocardial recovery consider 
withdrawal of medical therapy with 
biomarker and imaging monitoring  
- -  
Figure 5 – Management of severe acute PPCM (adapted from the HFA ESC Study Group on PPCM 
guidelines for the management of severe acute PPCM) 
 
 
 
